mivocabtagene autoleucel
An investigational treatment for Stiff Person Syndrome and Myasthenia Gravis.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify mivocabtagene autoleucel wherever you encounter it, plus the key facts at a glance.
- Generic name
- mivocabtagene autoleucel
- Development codes
- KYV-101, miv-cel
- Drug class
- CD19-directed CAR T-cell therapy
- Manufacturer
- Kyverna Therapeutics
- How it's taken
- One infusion into a vein after 3 days of chemotherapy, in a trial only
An investigational one-time CAR T-cell therapy from Kyverna Therapeutics, made from a person's own T cells and engineered to find and clear B cells that carry the marker CD19[3][1].
- Kyverna announced on November 12, 2026 that it had completed its FDA application for miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome and asked for priority review[1].
- The application rests on KYSA-8, a single-arm Phase 2 study in 26 treated adults, and a November 16, 2026 correction to a BioSpace article said the FDA had not yet accepted it for review[3][2].
- Miv-cel is also in a Phase 2/3 trial in generalized myasthenia gravis and is not approved anywhere for any use[8][1].
We'll email you when the FDA acts on mivocabtagene autoleucel and when new trials for the condition you pick open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where mivocabtagene autoleucel fits
Miv-cel is an experimental one-time CAR T-cell therapy from Kyverna Therapeutics that was submitted to the FDA in November 2026 for stiff person syndrome, based on a single-arm Phase 2 study[1][3].
- Diazepam's FDA label names stiff-man syndrome, as an add-on for relief of muscle spasm[14].
- Diazepam and baclofen are the first-line treatments for stiff person syndrome, and IVIG has the most supporting evidence among the immune treatments used when those are not enough, according to a 2024 review in the Handbook of Clinical Neurology[15].
- Other studies listed on ClinicalTrials.gov test a 10% IVIG product from Kedrion against placebo (not yet recruiting), efgartigimod at Thomas Jefferson University (recruiting) and the University of South Florida (not yet recruiting), and an early-stage donor-derived CAR T approach from CRISPR Therapeutics (not yet recruiting)[10][11][12][13].
- Miv-cel has not been compared with diazepam, IVIG or any other stiff person syndrome treatment in a trial, because KYSA-8 had no comparison group[7].
- Miv-cel involves chemotherapy before the infusion and long-term follow-up afterward, so a question to bring to a neurologist is how its known side effects and time commitment weigh against a person's current treatment[3][9].
How mivocabtagene autoleucel works
Stiff person syndrome is an autoimmune disease of the brain and spinal cord, and antibodies against an enzyme called glutamic acid decarboxylase (GAD) are the ones most often found, though their role in causing the disease is still uncertain, according to a 2024 review[15]. KYSA-6, the myasthenia gravis trial, enrolls people who carry AChR or MuSK antibodies[8].
Miv-cel starts with a collection of a person's own white blood cells. A lab adds a gene that gives the T cells a receptor, called a chimeric antigen receptor or CAR, that locks onto CD19, a protein on the surface of B cells[3]. Kyverna describes the CAR as fully human, with a CD28 signal that helps the cells switch on[1][3].
Before the infusion, people receive 3 days of low-dose chemotherapy with fludarabine and cyclophosphamide, called lymphodepletion[3]. After the infusion, the KYSA-8 researchers reported that B cells were cleared from the blood, along with changes they described as suggestive of an immune reset[3]. Whether the effect lasts for years is what long-term follow-up is meant to show[3][9].
Clinical trial results
KYSA-8 (NCT06588491) was a single-arm, open-label Phase 2 study with no placebo group, run at 3 US centers in Aurora (Colorado), Rochester (Minnesota) and Philadelphia[7][3]. It enrolled 27 adults aged 18 to 75 with antibody-positive stiff person syndrome that had not responded well enough to immune treatments, and 26 were treated (median age 56, 16 women)[3].
The main measure was the change in the time needed to walk 25 feet at week 16[3]. JAMA Neurology published the primary analysis online on November 9, 2026: walking time improved by a mean of 7.69 seconds and a median of 4.8 seconds, a 45.6% median improvement, and the 16 people who had reached week 24 kept a median improvement of 44.4%[3].
All 4 secondary measures, covering disability (modified Rankin Scale), how widespread stiffness is, sensitivity to triggers such as noise and touch, and walking ability, also improved at week 16[3]. At last follow-up, a median of 6.5 months, all treated people were off immune treatments for stiff person syndrome, the paper reports[3].
Kyverna first reported 1-year KYSA-8 results on September 24, 2026 and presented the full 1-year data set on October 21, 2026: a median walking time improvement of 49%, 20 of 26 people (77%) with at least a 20% improvement, 24 of 26 (92%) off chronic immune treatments, and 8 of the 12 who had needed a walking aid no longer needing one[5][4].
These figures come from Kyverna and have not been published in a journal yet. KYSA-8 had no comparison group, so its results cannot show how miv-cel compares with any other treatment[7].
KYSA-6 (NCT06193889) is a Phase 2/3 trial in generalized myasthenia gravis[8]. In its Phase 2 part, Kyverna reported on September 24, 2026 that 7 people had mean drops of 8.3 points on the MG-ADL daily activities score and 11.7 points on the QMG strength score at 24 weeks, and that 57% had minimal symptoms at last follow-up[5]. The Phase 3 part assigns about 60 people by chance to miv-cel or to continuing their standard immune treatment, with the option to switch to miv-cel after 24 weeks, and its main measures are MG-ADL and QMG at 24 weeks[5][8].
Kyverna said on November 12, 2026 that it expects enrollment to finish in mid-2027[1].
Main registered trial: NCT06193889 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Side effects and safety
- Blood counts after the lymphodepleting chemotherapy and infusion
- Long-term follow-up for up to 15 years in a Kyverna study
In the published KYSA-8 analysis of 26 people, cytokine release syndrome, an immune reaction that can cause fever and low blood pressure, occurred in 24 (92.3%): grade 1 in 10 and grade 2 in 14, with no higher grades[3]. ICANS, a nerve-related side effect of CAR T cells that can cause confusion, occurred in 3 people (11.5%), all grade 1, and all of these events resolved without lasting effects, according to the paper[3].
The most common severe side effect linked to treatment was a low neutrophil count (neutropenia), at grade 3 or 4 in 5 people (19.2%)[3]. Kyverna reported on October 21, 2026 that at 1 year 3 people had serious treatment-related side effects, all fully resolved, and that no case of IEC-HS, a rare overactive immune reaction, had occurred[4].
KYSA-8 left out people with a heart pumping fraction of 40% or lower, and people with a history of stroke, seizures or other brain diseases that could raise the risk[7]. Kyverna runs a separate study that follows people treated with miv-cel for up to 15 years, tracking side effects, new cancers, infections and new nerve or autoimmune problems[9]. Any warnings for an approved product would be set by an FDA label.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking mivocabtagene autoleucel
Given once, in trials only, as an infusion into a vein of the person's own engineered T cells[3]. In KYSA-8, people first had a collection of white blood cells, then 3 days of low-dose lymphodepleting chemotherapy (fludarabine 30mg/m² and cyclophosphamide 300mg/m² a day), then a single infusion of about 100 million CAR T cells[3]. Kyverna describes the treatment as a single dose[1]. Any approved dose and setting would be set by an FDA label.
Development history
KYSA-8 was first posted on ClinicalTrials.gov on September 19, 2024 and enrolled from September 2024 to May 2025[7][3]. On December 15, 2025 Kyverna announced positive topline KYSA-8 results and said miv-cel held both Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designations for stiff person syndrome[6]. Kyverna reported 1-year KYSA-8 data on September 24, 2026 and presented the full data set on October 21, 2026, and JAMA Neurology published the primary analysis on November 9, 2026[5][4][3].
On November 12, 2026 Kyverna announced that its rolling application to the FDA was complete, that it had asked for priority review, and that miv-cel holds RMAT designations in stiff person syndrome, generalized myasthenia gravis and non-active secondary progressive multiple sclerosis[1]. The same release said Kyverna had stopped prioritizing KYV-102, a related CAR T program[1].
BioSpace corrected an article on November 16, 2026 to say the application had been submitted but not yet accepted for review by the FDA[2]. Kyverna has not announced an FDA decision date.
Access and eligibility
Not approved, and available only in a trial. KYSA-8 for stiff person syndrome has finished[7]. KYSA-6 is recruiting adults 18 to 75 with generalized myasthenia gravis who have AChR or MuSK antibodies, an MG-ADL score of 6 or higher and a QMG score of 11 or higher, and whose disease did not respond to 2 or more immune treatments, or to 1 along with ongoing plasma exchange or IVIG[8]. It leaves out people who had a thymectomy within 12 months, any earlier gene or CAR T therapy, or a history of stroke with lasting effects or seizures, and people who used rituximab or another anti-CD20 or anti-CD19 antibody within 12 weeks[8]. ClinicalTrials.gov lists 10 recruiting US sites, in Los Angeles, Orange and Palo Alto (California), Miami, Indianapolis, Columbia (Missouri), Portland (Oregon), Philadelphia, Houston and Murray (Utah), among 22 sites in 6 countries[8].
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Explore Stiff Person Syndrome and Myasthenia Gravis trials
Other Stiff Person Syndrome & Myasthenia Gravis treatments
Common questions about mivocabtagene autoleucel
▸What is mivocabtagene autoleucel?
An investigational one-time CAR T-cell therapy from Kyverna Therapeutics, made from a person's own T cells and engineered to find and clear B cells that carry the marker CD19[3][1]. Kyverna announced on November 12, 2026 that it had completed its FDA application for miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome and asked for priority review[1]. The application rests on KYSA-8, a single-arm Phase 2 study in 26 treated adults, and a November 16, 2026 correction to a BioSpace article said the FDA had not yet accepted it for review[3][2]. Miv-cel is also in a Phase 2/3 trial in generalized myasthenia gravis and is not approved anywhere for any use[8][1].
▸How does mivocabtagene autoleucel work?
Stiff person syndrome is an autoimmune disease of the brain and spinal cord, and antibodies against an enzyme called glutamic acid decarboxylase (GAD) are the ones most often found, though their role in causing the disease is still uncertain, according to a 2024 review[15]. KYSA-6, the myasthenia gravis trial, enrolls people who carry AChR or MuSK antibodies[8].
Miv-cel starts with a collection of a person's own white blood cells. A lab adds a gene that gives the T cells a receptor, called a chimeric antigen receptor or CAR, that locks onto CD19, a protein on the surface of B cells[3]. Kyverna describes the CAR as fully human, with a CD28 signal that helps the cells switch on[1][3].
Before the infusion, people receive 3 days of low-dose chemotherapy with fludarabine and cyclophosphamide, called lymphodepletion[3]. After the infusion, the KYSA-8 researchers reported that B cells were cleared from the blood, along with changes they described as suggestive of an immune reset[3]. Whether the effect lasts for years is what long-term follow-up is meant to show[3][9].
▸What are the side effects of mivocabtagene autoleucel?
In the published KYSA-8 analysis of 26 people, cytokine release syndrome, an immune reaction that can cause fever and low blood pressure, occurred in 24 (92.3%): grade 1 in 10 and grade 2 in 14, with no higher grades[3]. ICANS, a nerve-related side effect of CAR T cells that can cause confusion, occurred in 3 people (11.5%), all grade 1, and all of these events resolved without lasting effects, according to the paper[3]. The most common severe side effect linked to treatment was a low neutrophil count (neutropenia), at grade 3 or 4 in 5 people (19.2%)[3]. Kyverna reported on October 21, 2026 that at 1 year 3 people had serious treatment-related side effects, all fully resolved, and that no case of IEC-HS, a rare overactive immune reaction, had occurred[4]. KYSA-8 left out people with a heart pumping fraction of 40% or lower, and people with a history of stroke, seizures or other brain diseases that could raise the risk[7]. Kyverna runs a separate study that follows people treated with miv-cel for up to 15 years, tracking side effects, new cancers, infections and new nerve or autoimmune problems[9]. Any warnings for an approved product would be set by an FDA label.
▸How is mivocabtagene autoleucel taken?
Given once, in trials only, as an infusion into a vein of the person's own engineered T cells[3]. In KYSA-8, people first had a collection of white blood cells, then 3 days of low-dose lymphodepleting chemotherapy (fludarabine 30mg/m² and cyclophosphamide 300mg/m² a day), then a single infusion of about 100 million CAR T cells[3]. Kyverna describes the treatment as a single dose[1]. Any approved dose and setting would be set by an FDA label.
▸Is mivocabtagene autoleucel FDA approved?
mivocabtagene autoleucel is currently in phase 3 clinical trials for Stiff Person Syndrome and Myasthenia Gravis. It has not yet received FDA approval.
▸Is miv-cel FDA approved for stiff person syndrome?
No. Miv-cel (KYV-101) is an experimental CAR T-cell therapy, and Kyverna announced on November 12, 2026 that it had completed its FDA application for stiff person syndrome.
FDA review: Kyverna asked for priority review, and a November 16, 2026 correction to a BioSpace article said the FDA had not yet accepted the application.
Decision date: Not announced.
Designations: RMAT and orphan drug designations for stiff person syndrome, according to Kyverna.
Source: Kyverna, November 12, 2026 and Kyverna, December 15, 2025
▸What did the KYSA-8 trial of miv-cel show?
In 26 treated adults, the time to walk 25 feet improved by a median of 45.6% at week 16, the main measure.
Other measures: Disability, stiffness, sensitivity to triggers and walking ability all improved at week 16.
Immune treatments: All treated people were off immune treatments for stiff person syndrome at last follow-up, a median of 6.5 months.
Design: Single arm with no placebo or comparison group.
▸What are the side effects of miv-cel?
In KYSA-8, the most common was cytokine release syndrome, in 24 of 26 people, all grade 1 or 2.
ICANS: Grade 1 in 3 of 26 people, all resolved.
Low blood counts: Grade 3 or 4 neutropenia in 5 of 26 people.
Before the infusion: 3 days of low-dose chemotherapy with fludarabine and cyclophosphamide.
▸Is miv-cel being tested for myasthenia gravis?
Yes. KYSA-6 is a Phase 2/3 trial in generalized myasthenia gravis that is recruiting.
Design: About 60 people assigned by chance to miv-cel or to continuing standard immune treatment, with a switch to miv-cel allowed after 24 weeks.
Main measures: MG-ADL and QMG scores at 24 weeks.
US sites: 10, in California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas and Utah.
Source: ClinicalTrials.gov NCT06193889 and Kyverna, September 24, 2026
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Kyverna Therapeutics via BioSpace (GlobeNewswire) · 2026-11-12. Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results. https://www.biospace.com/press-releases/kyverna-therapeutics-announces-completion-of-bla-submission-for-miv-cel-in-stiff-person-syndrome-and-reports-third-quarter-2026-financial-results
- BioSpace · 2026-11-16. Arrowhead's Ionis problem, Kyverna's next-gen end and more biotech earnings. https://www.biospace.com/business/arrowheads-ionis-problem-kyvernas-next-gen-end-and-more-biotech-earnings
- JAMA Neurology · 2026-11-09. Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome: A Nonrandomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/43002394/
- Kyverna Therapeutics via BioSpace (GlobeNewswire) · 2026-10-21. Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto. https://www.biospace.com/press-releases/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto
- Kyverna Therapeutics via BioSpace (GlobeNewswire) · 2026-09-24. Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis. https://www.biospace.com/press-releases/kyverna-therapeutics-reports-positive-one-year-data-demonstrating-durable-clinical-responses-and-favorable-safety-profile-for-miv-cel-in-stiff-person-syndrome-and-generalized-myasthenia-gravis
- Kyverna Therapeutics via BioSpace (GlobeNewswire) · 2025-12-15. Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome. https://www.biospace.com/press-releases/kyverna-therapeutics-announces-positive-topline-data-from-registrational-kysa-8-trial-of-miv-cel-kyv-101-in-stiff-person-syndrome
- ClinicalTrials.gov. KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome. https://clinicaltrials.gov/study/NCT06588491
- ClinicalTrials.gov. KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis. https://clinicaltrials.gov/study/NCT06193889
- ClinicalTrials.gov. A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101. https://clinicaltrials.gov/study/NCT07403188
- ClinicalTrials.gov. A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome. https://clinicaltrials.gov/study/NCT07552987
- ClinicalTrials.gov. VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS). https://clinicaltrials.gov/study/NCT07860021
- ClinicalTrials.gov. Efgartigimod for Stiff Person Syndrome (ESPS). https://clinicaltrials.gov/study/NCT06528392
- ClinicalTrials.gov. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease. https://clinicaltrials.gov/study/NCT07804004
- DailyMed · 2025-12-03. DIAZEPAM- diazepam oral solution DIAZEPAM (diazepam oral solution- concentrate solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdb839fb-27e5-4a11-aed6-da0a7ab6e996
- Handbook of Clinical Neurology via PubMed · 2024. Stiff person syndrome. https://pubmed.ncbi.nlm.nih.gov/39174250/